Document Detail


Regional P-glycoprotein activity and inhibition at the human blood-brain barrier as imaged by positron emission tomography.
MedLine Citation:
PMID:  20336065     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We used positron emission tomography (PET) to evaluate the contribution of P-glycoprotein (P-gp), present at the human blood-brain barrier (BBB), to regional drug distribution in the brain. Eleven healthy volunteers underwent PET imaging with [(11)C]-verapamil before and during cyclosporine A infusion. Regional P-gp inhibition was expressed as cyclosporine A-induced percentage change in the distributional clearance of verapamil (K(1)) in the brain, normalized to the regional blood flow (rCBF). K(1) estimates were similar across gray-matter regions of the brain and lower in the white matter regions, but all these estimates were considerably lower than rCBF. Normalization of K(1) by rCBF diminished the differences in estimates related to gray matter and white matter. In contrast, the K(1) for the pituitary, which is situated outside the BBB, approximated the rCBF. The magnitude of P-gp inhibition was comparable across BBB-protected brain structures. Our results indicate that P-gp and its inhibition equally affect the distribution of drugs (and therefore their neuro-efficacy and toxicity) in the various brain regions protected by the BBB.
Authors:
S Eyal; B Ke; M Muzi; J M Link; D A Mankoff; A C Collier; J D Unadkat
Related Documents :
11522575 - Changes in brain activity related to eating chocolate: from pleasure to aversion.
1354845 - Measuring the neuromodulatory effects of drugs in man with positron emission tomography.
2624815 - Double tracer autoradiographic method for sequential evaluation of regional cerebral pe...
19848545 - Changes in regional cerebral blood flow and glucose metabolism following electroacupunc...
1965525 - Myocardial ischemia--metabolic pathways and implications of increased glycolysis.
9166805 - Postoperative color doppler flow ultrasonographic assessment of ureteral patency in gyn...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, N.I.H., Extramural     Date:  2010-03-24
Journal Detail:
Title:  Clinical pharmacology and therapeutics     Volume:  87     ISSN:  1532-6535     ISO Abbreviation:  Clin. Pharmacol. Ther.     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-04-21     Completed Date:  2010-05-03     Revised Date:  2011-09-26    
Medline Journal Info:
Nlm Unique ID:  0372741     Medline TA:  Clin Pharmacol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  579-85     Citation Subset:  AIM; IM    
Affiliation:
Department of Pharmaceutics, University of Washington, Seattle, Washington, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Blood-Brain Barrier / drug effects*,  radionuclide imaging*
Brain / drug effects,  metabolism,  radionuclide imaging*
Cyclosporine / metabolism,  pharmacology
Female
Humans
Male
Middle Aged
P-Glycoprotein / antagonists & inhibitors*,  genetics,  metabolism*
Positron-Emission Tomography / methods*
Young Adult
Grant Support
ID/Acronym/Agency:
R33 AG031485/AG/NIA NIH HHS; R33 AG031485-01/AG/NIA NIH HHS
Chemical
Reg. No./Substance:
0/ABCB1 protein, human; 0/P-Glycoprotein; 59865-13-3/Cyclosporine
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Adaptive-Optimal Design in PET Occupancy Studies.
Next Document:  Pharmacokinetics, Pharmacodynamics, and Tolerability of Aleglitazar in Patients With Type 2 Diabetes...